Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2016 June;64(3) > Minerva Cardioangiologica 2016 June;64(3):339-53

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints
Cite this article as

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

REVIEWS  


Minerva Cardioangiologica 2016 June;64(3):339-53

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Advances with polymer-free amphilimus-eluting stents

Didier CARRIÉ

Department of Cardiology, University Hospital Rangueil, Toulouse, France


PDF  


Despite the improved clinical outcomes following the availability of second generation drug eluting stents (DES), percutaneous coronary intervention (PCI) is associated with worse clinical and angiographic outcomes among the patients with diabetes mellitus (DM) than among non-diabetics. The Cre8 Amphilimus-eluting DES is polymer-free, resulting in a reduced inflammatory response and lower risk of stent thrombosis. In a clinical study, it showed equivalent efficacy and safety in diabetic and non-diabetic populations, a unique finding among DES studies. These findings were confirmed in a real-world study, Investig8, and another real-world study, Particip8, is ongoing. The RESERVOIR Clinical Trial recruited patients with DM and showed noninferiority of the Cre8 DES compared to an everolimus eluting DES (EES) in the overall group but showed a statistical superiority of Cre8 in diabetic patients with higher metabolic dysfunctions. The Cre8 DES is therefore a valuable option for this important patient population.

top of page

Publication History

Cite this article as

Carrié D. Advances with polymer-free amphilimus-eluting stents. Minerva Cardioangiol 2016 June;64(3):339-53. 

Corresponding author e-mail

carrie.didier@chu-toulouse.fr